Richard Pulik Biography and Net Worth

CFO of Roivant Sciences

Richard Pulik serves as Chief Financial Officer of Roivant Sciences. Mr. Pulik joined Roivant in September 2021 and brings over twenty years of industry experience. Prior to joining Roivant, Mr.Pulik was the Global Head of Business Development & Licensing and Portfolio Management, Oncology at Novartis and a member of Novartis's Innovation Management Board and the Novartis Oncology Leadership Team. Mr. Pulik joined Novartis in 2012 as a Senior Director, Mergers & Acquisitions based in Basel, Switzerland. Earlier in his career Mr. Pulik worked at Bank of America Merrill Lynch, Monitor Group and UBS Investment Bank, focusing on mergers and acquisitions and strategy in the healthcare sector.

Mr. Pulik received a B.S. in Finance from The Wharton School and a B.A. in Economics and International Relations at the University of Pennsylvania in 2001. He grew up in Slovakia, Austria and Boston, and is passionate about delivering meaningful medicines to patients globally.

What is Richard Pulik's net worth?: The estimated net worth of Richard Pulik is at least $5.31 million as of December 23rd, 2025. Pulik owns 239,413 shares of Roivant Sciences stock worth more than $5,305,392 as of January 12th. This net worth estimate does not reflect any other assets that Pulik may own. Learn More about Richard Pulik's net worth.
How old is Richard Pulik?: Pulik is currently 45 years old. There are 5 older executives and no younger executives at Roivant Sciences. The oldest executive at Roivant Sciences is Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management, who is 56 years old. Learn More on Richard Pulik's age.
How do I contact Richard Pulik?: The corporate mailing address for Pulik and other Roivant Sciences executives is Clarendon House, 2 Church Street, Hamilton Parish HM 11. Roivant Sciences can also be reached via phone at 44-20-7400-3347 and via email at [email protected]. Learn More on Richard Pulik's contact information.
Has Richard Pulik been buying or selling shares of Roivant Sciences?: Richard Pulik has not been actively trading shares of Roivant Sciences during the last quarter. Most recently, Richard Pulik sold 406,731 shares of the business's stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $22.43, for a transaction totalling $9,122,976.33. Following the completion of the sale, the chief financial officer now directly owns 239,413 shares of the company's stock, valued at $5,370,033.59. Learn More on Richard Pulik's trading history.
Who are Roivant Sciences' active insiders?: Roivant Sciences' insider roster includes Matthew Gline (CEO), Daniel Gold (Director), Rakhi Kumar (CAO), Keith Manchester (Director), Richard Pulik (CFO), Vivek Ramaswamy (Major Shareholder), Mayukh Sukhatme (President and Chief Investment Officer), and Eric Venker (COO). Learn More on Roivant Sciences' active insiders.
Are insiders buying or selling shares of Roivant Sciences?: In the last year, Roivant Sciences insiders bought shares 3 times. They purchased a total of 33,514,991 shares worth more than $686,950,143.05. In the last year, insiders at the sold shares 50 times. They sold a total of 22,321,353 shares worth more than $393,736,676.11. The most recent insider tranaction occured on December, 31st when insider Mayukh Sukhatme sold 1,018,995 shares worth more than $22,122,381.45. Insiders at Roivant Sciences own 10.8% of the company. Learn More about insider trades at Roivant Sciences.
Information on this page was last updated on 12/31/2025.

Richard Pulik Insider Trading History at Roivant Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/23/2025	Sell	406,731	$22.43	$9,122,976.33	239,413
3/1/2023	Sell	1,912	$8.08	$15,448.96	223,347

Richard Pulik Buying and Selling Activity at Roivant Sciences

Roivant Sciences Company Overview

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Today's Range

Now: $22.16

$21.57

$22.28

50 Day Range

MA: $21.26

$19.87

$22.94

2 Week Range

Now: $22.16

$8.73

$23.47

Volume

4,936,937 shs

Average Volume

6,278,654 shs

Market Capitalization

$15.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Richard Pulik Biography and Net Worth

What is Richard Pulik's net worth?

How old is Richard Pulik?

How do I contact Richard Pulik?

Has Richard Pulik been buying or selling shares of Roivant Sciences?

Who are Roivant Sciences' active insiders?

Are insiders buying or selling shares of Roivant Sciences?